U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07214727) titled 'A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease' on Oct. 06.
Brief Summary: The purpose of this study is to:
* Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD)
* Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
Study Start Date: Oct. 09
Study Type: INTERVENTIONAL
Condition:
Alzheimer's Disease
Intervention:
DRUG: ALN-5288
ALN-5288 will be administered IT.
DRUG: Placebo
Placebo will be administered IT.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Alnylam Pharmaceuticals
Disclaimer: Cura...